Latest News and Press Releases

Clear confirmation of efficacy of Cynata’s proprietary Cymerus™ MSCs in second preclinical asthma studyTreatment with Cymerus MSCs in clinically-relevant model caused significantly greater reduction...

MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to provide an update on the progress...

MELBOURNE, Australia, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), announced today it will be featured as a...

Clear efficacy data for Cynata’s proprietary Cymerus™ MSCs in second preclinical study in a clinically-relevant model of asthmaCymerus MSCs caused significantly greater reduction of airway...

Cynata Pre-IND meeting with the US FDA completed successfullyFDA confirms Cymerus™ manufacturing dossier meets expectationsClear path determined for preclinical and clinical protocol requirements for...

Application filed with IP Australia would expand patent estate to immunotherapyCreates new opportunities in the growing field of immunotherapy and reinforces a position in oncology MELBOURNE,...